India Globalization Capital

India Globalization Capital, Inc. engages in the development and commercialization of cannabinoid based alternative therapies for indications, such as Alzheimer's disease, Parkinson's disease, and pain. The firm is involved in researching the application of cannabinoids, such as Tetrahydrocannabinol and Cannabidiol in combination with other compounds to address various ailments, including Alzheimer's disease. It operates through the Infrastructure Business and Life Sciences segments. The Infrastructure Business segment is involved in the rental of heavy construction equipment, execution of construction contracts, and purchase and resale of physical commodities used in infrastructure. The Life Sciences segment includes a biotech component, and a vertically integrated hemp-cannabinoid based healthcare and wellness business, which involves the production of plant and cannabinoid-based products, and therapies. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

IGC Pharma, Inc. is a clinical-stage pharmaceutical company that is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness. It has two investigational drug assets targeting Alzheimer's disease: IGC-AD1, which is in a Phase 2 clinical trial as a treatment for agitation in dementia due to Alzheimer's and TGR-63 that is in pre-clinical development. In addition to its drug development pipeline, IGC Pharma seeks to leverage artificial intelligence (AI) for Alzheimer's research. The company was founded by Ram Mukunda on April 29, 2005 and is headquartered in Potomac, MD.

IGC Reports Financial Results for Second Fiscal Quarter Ended Sept. 30, 2022

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Announces Issuance of Second Patent for the Treatment of Alzheimer's Using THC.

IGC Announces Issuance of Second Patent for the Treatment of Alzheimer's Using THC

Applied Optoelectronics

Bright Minds Biosciences

Alaunos Therapeutics

Penny stocks to buy? High volume has placed them on the watch list in the stock market today.

4 High Volume Penny Stocks To Watch While The Stock Market Is Down

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC announces that at its ASM on Sep 9'22 all proposals as disclosed on the DEF 14A were passed by the requisite stockholders vote.

IGC Announces Results of its 2022 Annual Stockholders Meeting

Agrify

Akanda Corp

Cronos Group

Greenlane Holdings

Akerna Corp

Leafly Holdings

WM Technology

Chicago Atlantic Real Estate Finance

Village Farms International

Zynerba Pharmaceuticals

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will continue to develop in 2022.

Weed Stocks This Week: Major Earnings Blitz

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC announces its financial results for the three months ended June 30, 2022, which is the first quarter of the Company's 2023 fiscal year.

IGC Reports Financial Results for the Quarter Ended June 30, 2022

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Reports Financial Results for Fiscal Year Ended March 31, 2022.

IGC Reports Financial Results for Fiscal Year Ended March 31, 2022

BETHESDA, Md.--(BUSINESS WIRE)-- #IGC--IGC is excited to announce that one of its subsidiaries reached an IP license agreement for a potential Alzheimer's drug development candidate.

IGC Acquires Exclusive Rights for a Potential Alzheimer's Drug Development Candidate

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--India Globalization Capital, Inc. (the “Company”) (NYSE American: IGC) announced today that the United States Patent and Trademark Office (“USPTO”) issued a patent (#11,351,152) to the Company titled “Method and Composition for Treating Seizure Disorders.” The patent is assigned to IGC and relates to compositions and methods for treating multiple types of seizure disorders and epilepsy in humans and animals, using a combination of the cannabinoid cannabidiol (CBD)

IGC Receives U.S. Patent for Method and Composition for Treating Seizure Disorders

POTOMAC, Md.--(BUSINESS WIRE)--India Globalization Capital, Inc. (IGC) Announces Final Approval of Settlement of Shareholder Class Action Lawsuits.

India Globalization Capital, Inc. (IGC) Announces Final Approval of Settlement of Shareholder Class Action Lawsuits

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC's Board appointed Ms. Claudia Grimaldi as a non-independent Director on Mar 23'22. IGC has 5 directors including a majority who are independent

India Globalization Capital Appoints Claudia Grimaldi to its Board of Directors

India Globalization Capital, Inc. IGC announced its financial results for the three months ending December 31, 2021 – quarter three of the company's 2022 fiscal year. Q3 Financial Highlights

India Globalization Capital Posts Net Loss Of $2.38M For The Third Quarter

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC announces its financial results for the three months ending December 31, 2021 – quarter three of the Company's 2022 fiscal year.

IGC Reports Financial Results for the December 31, 2021 Quarter

GREENBELT, Md., Jan. 31, 2022 /PRNewswire/ -- The Rosen Law Firm, P.A.

The Rosen Law Firm, P.A. and Pomerantz LLP Announce Proposed Securities Class Action Settlement on Behalf of Purchasers of India Globalization Capital, Inc. common stock - IGC

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--IGC Appoints Former Congressman Jim Moran to its Board of Directors.

India Globalization Capital Appoints Former Congressman Jim Moran to Its Board of Directors

POTOMAC, Md.--(BUSINESS WIRE)-- #IGC--Clinical Trial on Alzheimer's Patients Indicates Positive Safety and Tolerability Data for IGC's THC-Based Investigational New Drug

Clinical Trial on Alzheimer's Patients Indicates Positive Safety and Tolerability Data for IGC's THC-Based Investigational New Drug

Flora Growth Corp

GrowGeneration Corp

High Tide

Jupiter Wellness

Tilray Brands

The Valens Co

Welcome back to our weekly series,  Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.

9 Hottest Stories from the Cannabis Sector This Week

POTOMAC, MD,--(BUSINESS WIRE)-- #IGC--IGC-AD1 Phase 1 Clinical Trial Provides Valuable Insights on Safe and Effective Dosing of IGC-AD1 for Alzheimer's Patients.

Phase 1 Clinical Trial Provides Valuable Insights on Safe and Effective Dosing of IGC-AD1 for Alzheimer's Patients

POTOMAC, Md.--(BUSINESS WIRE)-- #Alzheimers--IGC Phase 1 Clinical Trial Data Indicate IGC's THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer's Patients.

Phase 1 Clinical Trial Data Indicate IGC's THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer's Patients

India Globalization Capital, Inc. (AMEX: IGC) reported its financial results Friday for the three months ended September 30, 2021, with revenue of $56,000, compared to $125,000 in the same period of 2020. The Bethesda, Maryland-based company noted that revenues in both quarters were primarily derived from its Life Sciences segment, which involved sales of products such as lotion, gummies and alcohol-based hand sanitizers.

IGC Posts Q2 Results, Reveals Promising Results From Clinical Trial Of THC-Drug For Alzheimer's Symptoms

BETHESDA, Md.--(BUSINESS WIRE)-- #Alzheimers--IGC announces its financial results for the three months ended September 30, 2021, which is the second quarter of the Company's 2022 fiscal year.

IGC Reports Financial Results for the September 30, 2021 Quarter

POTOMAC, Md.--(BUSINESS WIRE)-- #Alzheimers--Voting on all matters as disclosed on the Def Proxy filed with the SEC on Sep 15'21 were passed at IGC's Annual Meeting of Shareholders on Oct 15'21.

IGC Announces Results of its 2021 Annual Stockholders Meeting

The stock price of India Globalization Capital, Inc. (NYSEAMERICAN: IGC) increased by over 15% pre-market. This is why it happened.

IGC Stock: Over 15% Increase Pre-Market Explanation

POTOMAC, Md.--(BUSINESS WIRE)-- #Alzheimers--IGC Completes its Phase 1 Clinical Trial on Alzheimer's Patients, Reports Safety and Tolerability.

IGC Completes its Phase 1 Clinical Trial on Alzheimer's Patients, Reports Safety and Tolerability

BETHESDA, Md.--(BUSINESS WIRE)-- #IGCAD1--IGC announces financial results for quarter ended Jun 30, 2021 & completion of Phase 1 clinical trial of IGC-AD1 to alleviate Alzheimer's symptoms.

IGC Reports Financial Results for the June 30, 2021, Quarter

News for India Globalization Capital Stock (IGC)